profit from every $100 of sales.
$0$100
AngioDynamics
$12.12+3.32% today
+0.8% in 1 year
1-year low $9.701-year high $16.13
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What AngioDynamics sold, what it kept, and what it did with the cash.
Sales went from $316 million in 2022 to $292 million in 2025, with -$34.0 million of profit last year.
SalesProfit
AngioDynamics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AngioDynamics | No profit yet | ||
 ResMed | 21.8× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads AngioDynamics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 316 | 339 | 304 | 292 | |
| 166 | 174 | 155 | 158 | |
| -18 | -19 | -34 | -24 | |
| 11 | 12 | -6 | 2 | |
| -27 | -52 | -184 | -34 | |
| -0.68 | -1.33 | -4.59 | -0.83 | |
| 52.4% | 51.4% | 50.9% | 53.9% | |
| -5.8% | -5.5% | -11.1% | -8.2% | |
| -8.4% | -15.5% | -60.7% | -11.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 553 | 533 | 318 | 280 |
| Cash | 29 | 45 | 76 | 56 |
| Total debt | 34 | 65 | 5 | – |
| Total liabilities | 128 | 154 | 112 | 97 |
| 424 | 378 | 206 | 183 | |
| 39 | 39 | 40 | 41 | |
| -3.1% | -3.3% | -12.7% | -10.4% | |
| -6.3% | -13.9% | -89.7% | -18.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | 0 | -28 | -10 | |
| 4 | 4 | 6 | 4 | |
| -11 | -4 | -34 | -15 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 2 | |
| 11 | 11 | 11 | 10 |
Valuation
- –
- –
- –
- 2.7×
- 1.7×
- –
- 261.1×
- -2.9%
- -6.7%
- 0.0%
Profitability
- 53.9%
- -8.2%
- -11.6%
- -1.2%
- -13.0%
- -26.1%
- -17.6%
- -12.0%
- -13.0%
- 8.9%
Growth
- −2.6%
- –
- +57.0%
- –
- +1.7%
Financial health
- 9.7×
- 0.00
- 0.0%
- -130.7×
- 2.35
- 1.47
- 1.20
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 948
Bottom 16%of 871
Bottom 12%of 868
Bottom 26%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 2, 2026 | -0.07 | -0.11 | +36.4% |
| Jan 6, 2026 | -0.15 | -0.10 | −50.0% |
| Oct 2, 2025 | -0.10 | -0.14 | +28.6% |
| Jul 15, 2025 | -0.03 | -0.13 | +76.9% |
| Apr 2, 2025 | 0.03 | -0.13 | +123.1% |
| Jan 8, 2025 | -0.04 | -0.11 | +63.6% |
| Oct 3, 2024 | -0.11 | -0.15 | +26.7% |
| Jul 16, 2024 | -0.06 | -0.20 | +70.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
38No pass
Philip Fisher
30No pass
Peter Lynch
29No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
16No pass
Questions about AngioDynamics
Is AngioDynamics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AngioDynamics AI analysis
What does AngioDynamics do?
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. It is in Medical - Instruments & Supplies.
Does AngioDynamics pay a dividend?
No. AngioDynamics does not pay a dividend at the moment; in 2025 it returned $1.67 million to shareholders by buying back its own shares.
Is AngioDynamics stock halal?
Yes. AngioDynamics passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has AngioDynamics stock done over the past year?
Up 0.8% over the past twelve months, to $12.12. It traded between $9.70 and $16.13 and is 24.9% below its high.
Who are AngioDynamics's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with AngioDynamics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.